Here, we present a metastatic ATC patient with PD-L1 positive (tumor proportion score of 60%) tumor and <i>NRAS</i> Q61R/<i>BRAF</i> D594N mutations, who progressed on PD-1 antibody sintilimab plus angiogenesis inhibitor anlotinib. Here, BRAF is linked to neoplasm.